TSE:APS Aptose Biosciences (APS) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free APS Stock Alerts C$1.62 -0.04 (-2.41%) (As of 04:17 PM ET) Add Compare Share Share Today's RangeC$1.59▼C$1.6650-Day RangeC$1.65▼C$2.7452-Week RangeC$1.59▼C$11.40Volume13,330 shsAverage Volume8,984 shsMarket CapitalizationC$25.45 millionP/E RatioN/ADividend Yield0.39%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesStock AnalysisChartCompetitorsEarningsHeadlinesInsider Trades Get Aptose Biosciences alerts: Email Address Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Aptose Biosciences Stock (TSE:APS)Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Read More APS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APS Stock News HeadlinesMarch 28, 2024 | seekingalpha.comAptose Biosciences Inc. (APTO) Q4 2023 Earnings Call TranscriptMarch 25, 2024 | benzinga.comAptose Biosciences's Earnings: A PreviewApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.January 31, 2024 | finance.yahoo.comAptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment OptionDecember 20, 2023 | theglobeandmail.comClosing Bell: Aptose Biosciences Inc flat on Wednesday (APS)December 9, 2023 | finance.yahoo.comAptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual MeetingNovember 30, 2023 | finance.yahoo.comAptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive RoleNovember 10, 2023 | finance.yahoo.comAptose Biosciences Inc. (NASDAQ:APTO) Q3 2023 Earnings Call TranscriptApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.November 9, 2023 | finance.yahoo.comAptose Reports Results for the Third Quarter 2023November 2, 2023 | theglobeandmail.comAptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual MeetingNovember 2, 2023 | finance.yahoo.comAptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual MeetingOctober 30, 2023 | finanznachrichten.deAptose Biosciences, Inc.: Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug TuspetinibOctober 26, 2023 | finance.yahoo.comAptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023October 20, 2023 | markets.businessinsider.comPromising Prospects of Tuspetinib Drive Buy Rating for Aptose Biosciences: An Analyst’s PerspectiveOctober 7, 2023 | theglobeandmail.comClosing Bell: Aptose Biosciences Inc up on Friday (APS)August 25, 2023 | theglobeandmail.comClosing Bell: Aptose Biosciences Inc up on Thursday (APS)August 22, 2023 | theglobeandmail.comClosing Bell: Aptose Biosciences Inc flat on Monday (APS)August 11, 2023 | finanznachrichten.deAptose Biosciences, Inc.: Aptose Reports Results for the Second Quarter 2023August 11, 2023 | finance.yahoo.comAptose Reports Results for the Second Quarter 2023August 7, 2023 | theglobeandmail.comAptose Biosciences: Top 10 Undervalued Biotechnology Industry Stocks (APS)July 21, 2023 | theglobeandmail.comAptose Biosciences: Stocks Undervalued by Analyst Consensus on TSX (APS)June 27, 2023 | finanznachrichten.deAptose Biosciences, Inc.: Aptose Biosciences Meets Nasdaq Minimum Bid Price ComplianceJune 5, 2023 | finanznachrichten.deAptose Biosciences, Inc.: Aptose Biosciences Provides Update on Reverse Stock SplitMay 31, 2023 | finance.yahoo.comAptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023May 26, 2023 | seekingalpha.comAptose to sell up to $25M stock in the U.S.May 17, 2023 | theglobeandmail.comClosing Bell: Aptose Biosciences Inc flat on Tuesday (APS)See More Headlines Receive APS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/26/2024Today4/25/2024Next Earnings (Estimated)5/13/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:APS CUSIPN/A CIKN/A Webaptose.com Phone+1-647-4799828FaxN/AEmployees31Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($10.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-51,210,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-225.00% Return on Assets-102.23% Debt Debt-to-Equity Ratio14.27 Current Ratio0.78 Quick Ratio5.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$1.04 per share Price / Cash Flow1.60 Book ValueC$1.03 per share Price / Book1.61Miscellaneous Outstanding Shares15,710,000Free FloatN/AMarket CapC$26.08 million OptionableNot Optionable Beta1.44 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. William G. Rice Ph.D. (Age 59)Chairman, Pres & CEO Mr. Gregory K. Chow CPA (Age 45)MBA, BA, Sr. VP, CFO & Principal Accounting Officer Mr. Ernest Kitt B.S.M.S, VP of Devel. & Technical OperationsDr. Stephen B. Howell (Age 73)Chief Medical Officer Mr. Peter MurrayDirector of Clinical Devel.Key CompetitorsAcasti PharmaCVE:ACSTCovalon TechnologiesCVE:COVLiberty BiopharmaCVE:LTYDevonian Health GroupCVE:GSDCeaproCVE:CZOView All Competitors APS Stock Analysis - Frequently Asked Questions How have APS shares performed in 2024? Aptose Biosciences' stock was trading at C$3.35 at the start of the year. Since then, APS shares have decreased by 51.9% and is now trading at C$1.61. View the best growth stocks for 2024 here. When is Aptose Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our APS earnings forecast. How were Aptose Biosciences' earnings last quarter? Aptose Biosciences Inc. (TSE:APS) announced its earnings results on Tuesday, March, 26th. The biotechnology company reported ($1.96) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.98) by $0.02. What other stocks do shareholders of Aptose Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aptose Biosciences (APTO), Aurinia Pharmaceuticals (AUPH), Advanced Micro Devices (AMD), NVIDIA (NVDA), Aurora Cannabis (ACB), Adobe (ADBE), AltaGas (ALA), Aphria (APHA), Algonquin Power & Utilities (AQN) and Badger Daylighting (BAD). How do I buy shares of Aptose Biosciences? Shares of APS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:APS) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyYour Money is Not SafeAmerican AlternativeThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
